Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001042728 | SCV001206428 | uncertain significance | not provided | 2022-10-25 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 1125 of the USH2A protein (p.Ile1125Met). This variant is present in population databases (rs143319658, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with USH2A-related conditions. ClinVar contains an entry for this variant (Variation ID: 840677). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt USH2A protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Blueprint Genetics | RCV001073676 | SCV001239229 | uncertain significance | Retinal dystrophy | 2019-08-09 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003455174 | SCV004182347 | uncertain significance | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001271231 | SCV004182348 | uncertain significance | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001042728 | SCV004224788 | uncertain significance | not provided | 2021-11-22 | criteria provided, single submitter | clinical testing | PM2_supporting |
ARUP Laboratories, |
RCV001042728 | SCV004563717 | uncertain significance | not provided | 2023-09-11 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001271231 | SCV001452240 | uncertain significance | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |